Rosetta Genomics Ltd. (Nasdaq:ROSG) and collaborators announced the results of a research study, showing for the first time that a microRNA-based diagnostic test can objectively identify squamous lung cancer with 96% sensitivity. The study, posted on the Journal of Clinical Oncology’s Web site,[1] was carried out in collaboration with researchers at Columbia University, NYU Cancer [...]